Tretten approved for genetic clotting disorder

(HealthDay)—Tretten (coagulation factor XIII A-Subunit recombinant) has been approved by the U.S. Food and Drug Administration to treat a very rare blood clotting disorder called congenital Factor XIII A-Subunit deficiency.

People with the do not make enough Factor XIII, a blood component that promotes clotting. Tretten, a human recombinant produced in , makes up for this deficiency, which could otherwise be life threatening, the FDA said Monday in a news release.

Tretten was evaluated in a clinical study of 77 people with the disorder. Administered monthly, it was effective in preventing bleeding in 90 percent of recipients. Side effects included headache, extremity pain and pain at the injection site. No study participant developed abnormal clotting, the FDA said.

The product was developed and is produced by Novo Nordisk, based in Denmark.


Explore further

FDA approves rixubis for prophylactic tx in hemophilia B

More information: To learn more about this disorder, visit the National Hemophilia Foundation.

Copyright © 2013 HealthDay. All rights reserved.

Citation: Tretten approved for genetic clotting disorder (2013, December 23) retrieved 22 May 2019 from https://medicalxpress.com/news/2013-12-tretten-genetic-clotting-disorder.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more